Quick Answer
Sensei Biotherapeutics, Inc. reported Stockholders Equity of $18.59 million for the year ending 2025.
- Sensei Biotherapeutics, Inc. showed a decrease of -51.6% in Stockholders Equity from 2024 to 2025.
- This data is from Sensei Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$42.89 million | Q2 2020: -$47.10 million | Q3 2020: -$51.68 million | Q1 2021: $171.25 million | Q2 2021: $163.13 million | Q3 2021: $155.21 million | Q1 2022: $135.31 million | Q2 2022: $125.92 million | Q3 2022: $113.99 million | Q1 2023: $94.85 million | Q2 2023: $79.20 million | Q3 2023: $71.00 million | Q1 2024: $58.47 million | Q2 2024: $52.19 million | Q3 2024: $45.78 million | Q1 2025: $31.99 million | Q2 2025: $27.31 million | Q3 2025: $23.01 million.
- Over the full 7 years of available data (2019 to 2025), Sensei Biotherapeutics, Inc.'s Stockholders Equity has grown by 127.1%.
- Historical annual values: Fiscal year 2025: $18.59 million | Fiscal year 2024: $38.39 million | Fiscal year 2023: $64.90 million | Fiscal year 2022: $103.41 million | Fiscal year 2021: $146.51 million | Fiscal year 2020: -$56.44 million | Fiscal year 2019: -$68.66 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: